Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($1.93) for the year, up from their prior forecast of ($1.97). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share.

A number of other brokerages also recently commented on ZVRA. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $8.11 on Friday. The company’s 50 day simple moving average is $8.79 and its 200-day simple moving average is $7.59. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The firm has a market cap of $432.88 million, a PE ratio of -4.12 and a beta of 2.01. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the business earned ($0.40) earnings per share.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in ZVRA. International Assets Investment Management LLC boosted its position in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the period. Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter worth about $92,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $94,000. Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $95,000. Finally, SG Americas Securities LLC acquired a new position in Zevra Therapeutics during the 3rd quarter worth approximately $105,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.